JonesTrading analyst Soumit Roy has maintained their bullish stance on TARA stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Soumit Roy’s rating is based on Protara Therapeutics’ progress with their bladder cancer drug, TARA-002, which is moving into a pivotal study for BCG-Naive patients. The company has received alignment from the FDA to conduct this trial, which will compare TARA-002 against physician’s choice of intravesical-delivered chemotherapy.
The trial’s primary endpoint is set as complete response (CR) at six months, which is considered a straightforward measure compared to other trials. Additionally, Protara has provided benchmarks for CR rates based on historical data, which supports the potential efficacy of TARA-002. These factors, combined with the company’s financial stability, contribute to the Buy rating.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $26.00 price target.